ARTICLE | Company News
Ergo, Louisiana State University metabolic news
October 23, 2000 7:00 AM UTC
ERGO paid $3.05 million to the university to resolve a dispute over the parties' 1995 agreement under which ERGO licensed technology from the university related to ERGO's Ergoset bromocriptine to treat Type II diabetes requiring insulin. The dispute regarded the amount of royalty ERGO owed the university following a 1998 $10 million equity purchase in ERGO by Johnson & Johnson (JNJ, New Brunswick, N.J.). At that time, JNJ was ERGO's partner for Ergoset (see BioCentury, Feb. 28). ...